

Biosimilars: Lower-Cost Alternatives Offer Same Benefits

Millions of Americans struggle to pay astronomical drug prices. Patients with chronic or life-threatening conditions often require complex and expensive biologic drugs, and the price can force them to choose between medication and other expenses.

Biosimilars can provide relief. Biosimilars are FDA-approved, similar versions of complex biologic drugs. As safe, less-expensive alternatives to brand-name biologics, they can be a valuable resource for patients and physicians. In fact, biosimilars cost an average of 35 to 43% less than their biologic counterparts.

Biosimilars are FDA-approved similar versions of complex biologic drugs.

Consumers who use an immunosuppressive drug to treat rheumatoid arthritis could save up to 35% using a biosimilar.



While the FDA has approved 12 biosimilars, anti-competitive business practices mean that consumers can only access 5 biosimilars in the United States.

Success overseas has shown the impact of biosimilars. European consumers have access to 36 biosimilars, leading to a competitive market that has helped lower prices.

More than one-third of doctors are not aware that biosimilars are as effective as biologics, and half of them are not aware that biosimilars are as safe.

Scripius is working to educate doctors and patients about these new therapies. In addition, we collaborate with physicians and pharmacists to implement strategies that facilitate biosimilar adoption, which could save more than \$4.8 million annually.